Universal Health Services, Inc.UHS
NYSE•Healthcare•Medical Care Facilities
Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities in the United States. It operates through Acute Care Hospital Services and Behavioral Health Care Services segments. The company's hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric, pharmacy, and/or behavioral health services. It also provides commercial health insurance services; capital resources; and various management services, including central purchasing, information services, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Universal Health Services, Inc. (UHS) reported trailing twelve months revenue of $17.76B as of March 2026, a 10.4% increase year-over-year. Quarterly revenue reached $4.50B, reflecting continued top-line momentum.
Universal Health Services, Inc. generated $1.52B in TTM net income, with quarterly EBITDA of $658.29M. The operating margin expanded from 11.1% to 11.2%, suggesting improving cost efficiency and pricing discipline.
The spread between operating margin (11.2%) and net margin (7.8%) indicates tight cost control with minimal non-operating drag. Net margin has improved from 7.7% a year ago, signaling stronger bottom-line efficiency.
UHS trades at a P/E of 7.4x (below the broader market average) and a P/S of 0.6x. The price-to-book ratio of 1.5x reflects a moderate premium to book value.
The company generated $184.47M in free cash flow over the trailing twelve months, a 52.4% increase year-over-year, indicating cash generation ability. The balance sheet shows $15.68B in total assets with $3.95B in long-term debt against $7.53B in stockholders equity for a debt-to-equity ratio of 0.5. Data based on the most recent quarterly reports.
Competitive analysis based on 21 quarters of fundamental data
Operating margins are expanding at ~11.2%, suggesting durable pricing power and cost discipline.
ROE averages 17.8% but has fluctuated — the competitive advantage may be cyclical or emerging.
8 of the last 8 quarters generated positive FCF. The company generally funds itself but has occasional cash consumption quarters.
TTM revenue has grown consistently (7 of 7 quarters up), with ~18.3% growth over the period. Strong demand durability.
Data-driven red flags and warnings across 21 quarters
Margins are stable or improving at ~11.5% — no sign of cost or pricing stress.
FCF consistently trails net income (avg 0.7x) — earnings may be inflated by non-cash items or aggressive accounting.
D/E ratio is 0.5 — conservative capital structure with low financial risk.
Revenue is stable or growing over recent quarters — demand appears durable.
Free cash flow is consistently positive — the business self-funds without external capital reliance.
Shares decreased 9.1% — net buybacks are reducing shares outstanding and boosting per-share value.
Quarterly standardized metrics.
Stock price and market valuation
Revenue and earnings growth across quarters
Assets, cash, debt, and leverage
Price multiples and return ratios
Operating efficiency and return metrics
Free cash flow, earnings quality, and capital allocation